Congress grants HHS funds to fight healthcare fraud
WASHINGTON The Department of Health and Human Services will get a funding increase of $250 million to fight healthcare fraud, according to published reports.
Bloomberg reported that Congress was set to vote in favor of giving HHS $1.7 million to fight criminal organizations that defraud Medicare.
The news organization reported that companies likely to benefit from the increase in funding included health insurers and companies that provide antifraud technology, such as McKesson Corp.
Mission launches Uribel
SAN ANTONIO Drug maker Mission Pharmacal has launched a treatment for urinary tract infections.
Mission announced the launch of Uribel (methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue and hyoscyamine sulfave) capsules, used to relieve local discomfort and inflammation associated with lower urinary tract infections, interstitial cystitis, painful bladder syndrome and urinary tract procedures.
Mission will handle distribution and marketing of Uribel for Star Pharmaceuticals, while an unnamed third party company will manufacture the drug.
“Uribel is an important expansion of our urology and women’s health product portfolio, and we’re excited to be partnering with Star Pharmaceuticals to bring this product to patients,” Mission president of commercial operations Terry Herring said. “Uribel provides three complementary ways to treat uncomfortable urinary tract conditions – an analgesic to relieve pain and burning, an antispasmodic to reduce urinary urgency and antiseptic that inhibits the growth of bacteria.”
Genzyme, Isis announce study results for mipomersen
CAMBRIDGE, Mass. Biotech company Genzyme and Isis Pharmaceuticals have finished late-stage clinical trials of a cholesterol-lowering drug, the two companies said.
Genzyme and Isis announced results of two phase 3 studies of the drug mipomersen in patients who have high cholesterol levels while taking high doses of cholesterol-lowering medications. The studies were conducted in North America, Europe and South Africa.
In one study of patients with severe hypercholesterolemia, mipomersen reduced “bad” LDL cholesterol by 36%, compared with 13% among those taking placebo; in the other study of patients with high cholesterol at high risk of cardiovascular disease, the drug reduced LDL cholesterol by 37%, compared with 5% among those taking placebo.